Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-BCMA-CART in R/R MM
NCT05308875Phase 1Not yet recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-PD1-CART in multiple myeloma (MM), sponsored by BRL Medicine Inc. Primary endpoint: Objective Response Rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
BCMA-PD1-CART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05308875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308875.